Prophylactic G-CSF use among patients receiving chemotherapy regimens with intermediate FN risk versus those receiving chemotherapy regimens with intermediate FN risk with ≥ 1 risk factor was similar across the 5 cancer types. Here, CSF3 is linked to cancer.